CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy

Chimeric antigen receptor (CAR)-engineered T lymphocytes (CAR Ts) produced impressive clinical results against selected hematological malignancies, but the extension of CAR T cell therapy to the challenging field of solid tumors has not, so far, replicated similar clinical outcomes. Many efforts are...

Descripción completa

Detalles Bibliográficos
Autores principales: Rotolo, Ramona, Leuci, Valeria, Donini, Chiara, Cykowska, Anna, Gammaitoni, Loretta, Medico, Giovanni, Valabrega, Giorgio, Aglietta, Massimo, Sangiolo, Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600566/
https://www.ncbi.nlm.nih.gov/pubmed/31212634
http://dx.doi.org/10.3390/ijms20112839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600566/
https://www.ncbi.nlm.nih.gov/pubmed/31212634
http://dx.doi.org/10.3390/ijms20112839

Ejemplares similares